Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Partnership
BARDA Partners with ICON to Execute Next Generation COVID-19 Vaccines Clinical Trial
Details : The partnership aims to execute a Phase 2b clinical trial to assess the relative efficacy of a next generation COVID-19 vaccine compared to currently approved/authorised COVID-19 vaccines in the prevention of symptomatic, PCR confirmed SARS-CoV-2 infecti...
Brand Name : Undisclosed
Molecule Type : Vaccine
Upfront Cash : Undisclosed
September 13, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : BARDA
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : AV7909
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : BARDA
Deal Size : Not Applicable
Deal Type : Not Applicable
ICON Selected By BARDA To Conduct Anthrax Vaccine Clinical Trial
Details : This clinical study will inform operational logistics and will not expose participants to anthrax. AV7909 is indicated for post-exposure prophylaxis of anthrax disease. Anthrax vaccine is also recommended for unvaccinated people of all ages who have been...
Brand Name : AV7909
Molecule Type : Vaccine
Upfront Cash : Not Applicable
October 06, 2022
Lead Product(s) : AV7909
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : BARDA
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : EG-009A
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Evergreen Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : The purpose of the study is to evaluate the efficacy of Evergreen’s EG-009A drug candidate for the treatment of moderate to severe COVID-19 cases.
Brand Name : EG-009A
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
June 18, 2021
Lead Product(s) : EG-009A
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Evergreen Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Recombinant human glutamic acid decarboxylase,Vitamin D
Therapeutic Area : Endocrinology
Study Phase : Phase II
Recipient : Diamyd Medical AB
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : All 50 patients who participated in the extension of Diamyd Medical's Phase IIb trial DIAGNODE-2 with the diabetes vaccine Diamyd® have now made their 24-month visit, and data will be presented in early July.
Brand Name : Diamyd
Molecule Type : Vaccine
Upfront Cash : Not Applicable
April 29, 2021
Lead Product(s) : Recombinant human glutamic acid decarboxylase,Vitamin D
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Recipient : Diamyd Medical AB
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?